FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007448214> ?p ?o ?g. }

• W2007448214 endingPage "2769" @default.
• W2007448214 startingPage "2760" @default.
• W2007448214 abstract "BACKGROUND. Human RNASET2 is a T2-RNase glycoprotein encoded by the RNASET2 gene, which is located on chromosome 6 (6q27). Deletion in 6q27 is associated with several human malignancies. BACKGROUND. A synthetic RNASET2 gene that was optimized for expression in the yeast Pichia pastoris was designed according to the cDNA sequence and was cloned under the control of the methanol-induced promoter fused to the α-mating secretion peptide. The recombinant protein was purified from the culture supernatant of transformed P. pastoris through an affinity Sepharose-concanavalin A column. Actin-binding activity was examined by membrane blotting using monoclonal mouse antiactin immunoglobulin M and by cross-linking in solution to G-actin using 1-[3-(dimethylamino)propyl]-3-ethyl-carboimide methiodide. The antiangiogenic activity of RNASET2 (from 0.5 μM to 10 μM) was assessed by a human umbilical vein endothelial (HUVE) cell assay in the presence of 1 μg/mL angiogenin, basic fibroblast growth factor (bFGF), or recombinant human vascular endothelial growth factor (VEGF). Cell colony formation was examined in human colon HT29 cancer cells to assess the antitumorigenic activity of RNASET2 or the enzymatic-inactivated RNASET2 (EI-RNASET2) (1 μM each). In an athymic mouse xenograft model, LS174T human cancer cells were injected subcutaneously. When tumors were palpable, the mice were treated for 3 weeks with RNASET2 (1 mg/kg), paclitaxel (10 mg/kg or 15 mg/kg), or a combination of the 2 drugs. RESULTS. The recombinant RNASET2 was identified as a 27-kilodalton glycoprotein that possessed the ability to bind actin in vitro. RNASET2 significantly inhibited clonogenicity in HT29 cells. EI-RNASET2 produced a similar effect, suggesting that its antitumorigenic activity is unrelated to its RNase activity. In HUVE cells, RNASET2 inhibited angiogenin-, bFGF-, and VEGF-induced tube formation in a dose-dependent manner. In athymic mice, RNASET2 inhibited the development of an LS174T-derived xenograft by 40%. A synergistic effect was obtained with combined RNASET2 and paclitaxel treatments. CONCLUSIONS. The current results suggested that RNASET2 represents a new class of antitumorigenic and antiangiogenic drugs, and the findings of this study emphasize the advantage of using agents like RNASET2 in combined therapy. Cancer 2006. © 2006 American Cancer Society." @default.
• W2007448214 created "2016-06-24" @default.
• W2007448214 creator A5049665310 @default.
• W2007448214 creator A5059809298 @default.
• W2007448214 creator A5060595352 @default.
• W2007448214 creator A5088169519 @default.
• W2007448214 creator A5090317639 @default.
• W2007448214 date "2006-01-01" @default.
• W2007448214 modified "2023-10-01" @default.
• W2007448214 title "A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics" @default.
• W2007448214 cites W1585025162 @default.
• W2007448214 cites W1964027303 @default.
• W2007448214 cites W1969741427 @default.
• W2007448214 cites W1978367446 @default.
• W2007448214 cites W1981311092 @default.
• W2007448214 cites W1992072921 @default.
• W2007448214 cites W2004013527 @default.
• W2007448214 cites W2010179095 @default.
• W2007448214 cites W201353814 @default.
• W2007448214 cites W2017915061 @default.
• W2007448214 cites W2024042048 @default.
• W2007448214 cites W2039519482 @default.
• W2007448214 cites W2040377351 @default.
• W2007448214 cites W2052056514 @default.
• W2007448214 cites W2059791006 @default.
• W2007448214 cites W2071318413 @default.
• W2007448214 cites W2077129920 @default.
• W2007448214 cites W2078161303 @default.
• W2007448214 cites W2079699168 @default.
• W2007448214 cites W2081633887 @default.
• W2007448214 cites W2082357659 @default.
• W2007448214 cites W2094297572 @default.
• W2007448214 cites W2100837269 @default.
• W2007448214 cites W2117795372 @default.
• W2007448214 cites W2126801813 @default.
• W2007448214 cites W2140786019 @default.
• W2007448214 cites W2165805421 @default.
• W2007448214 cites W2331541144 @default.
• W2007448214 cites W2749830096 @default.
• W2007448214 cites W4230271494 @default.
• W2007448214 cites W4239593130 @default.
• W2007448214 doi "https://doi.org/10.1002/cncr.22327" @default.
• W2007448214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17109444" @default.
• W2007448214 hasPublicationYear "2006" @default.
• W2007448214 type Work @default.
• W2007448214 sameAs 2007448214 @default.
• W2007448214 citedByCount "55" @default.
• W2007448214 countsByYear W20074482142012 @default.
• W2007448214 countsByYear W20074482142013 @default.
• W2007448214 countsByYear W20074482142014 @default.
• W2007448214 countsByYear W20074482142015 @default.
• W2007448214 countsByYear W20074482142016 @default.
• W2007448214 countsByYear W20074482142017 @default.
• W2007448214 countsByYear W20074482142018 @default.
• W2007448214 countsByYear W20074482142019 @default.
• W2007448214 countsByYear W20074482142020 @default.
• W2007448214 countsByYear W20074482142021 @default.
• W2007448214 countsByYear W20074482142022 @default.
• W2007448214 countsByYear W20074482142023 @default.
• W2007448214 crossrefType "journal-article" @default.
• W2007448214 hasAuthorship W2007448214A5049665310 @default.
• W2007448214 hasAuthorship W2007448214A5059809298 @default.
• W2007448214 hasAuthorship W2007448214A5060595352 @default.
• W2007448214 hasAuthorship W2007448214A5088169519 @default.
• W2007448214 hasAuthorship W2007448214A5090317639 @default.
• W2007448214 hasBestOaLocation W20074482141 @default.
• W2007448214 hasConcept C104317684 @default.
• W2007448214 hasConcept C108625454 @default.
• W2007448214 hasConcept C153911025 @default.
• W2007448214 hasConcept C187882448 @default.
• W2007448214 hasConcept C2776719180 @default.
• W2007448214 hasConcept C2777313579 @default.
• W2007448214 hasConcept C2780394083 @default.
• W2007448214 hasConcept C2781372317 @default.
• W2007448214 hasConcept C40767141 @default.
• W2007448214 hasConcept C502942594 @default.
• W2007448214 hasConcept C55493867 @default.
• W2007448214 hasConcept C86803240 @default.
• W2007448214 hasConceptScore W2007448214C104317684 @default.
• W2007448214 hasConceptScore W2007448214C108625454 @default.
• W2007448214 hasConceptScore W2007448214C153911025 @default.
• W2007448214 hasConceptScore W2007448214C187882448 @default.
• W2007448214 hasConceptScore W2007448214C2776719180 @default.
• W2007448214 hasConceptScore W2007448214C2777313579 @default.
• W2007448214 hasConceptScore W2007448214C2780394083 @default.
• W2007448214 hasConceptScore W2007448214C2781372317 @default.
• W2007448214 hasConceptScore W2007448214C40767141 @default.
• W2007448214 hasConceptScore W2007448214C502942594 @default.
• W2007448214 hasConceptScore W2007448214C55493867 @default.
• W2007448214 hasConceptScore W2007448214C86803240 @default.
• W2007448214 hasIssue "12" @default.
• W2007448214 hasLocation W20074482141 @default.
• W2007448214 hasLocation W20074482142 @default.
• W2007448214 hasOpenAccess W2007448214 @default.
• W2007448214 hasPrimaryLocation W20074482141 @default.
• W2007448214 hasRelatedWork W2012204162 @default.
• W2007448214 hasRelatedWork W2028296689 @default.
• W2007448214 hasRelatedWork W2092716771 @default.

• next